The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.

Nyholm B, Orskov L, Hove KY, Gravholt CH, Møller N, Alberti KG, Moyses C, Kolterman O, Schmitz O

Metabolism: clinical and experimental1 Jul 1999Cited by 80 (Europe PMC)

PMID10421239DOI10.1016/s0026-0495(99)90232-9PepBankPUB-10421239

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, pramlintide reduced serum fructosamine versus placebo.
In plain wordsIn men with type 1 diabetes, pramlintide reduced fructosamine compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseSerum fructosamine
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Measurements
Serum fructosamine
314 micromol/L
pramlintide, +/-14
Serum fructosamine
350 micromol/L
placebo, +/-14
Source sentences
Summary
Serum fructosamine was decreased after pramlintide (314+/-14 micromol/L) compared with placebo (350+/-14 micromol/L, P = .008).
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123901
02HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, pramlintide reduced mean plasma glucose versus placebo.
In plain wordsIn men with type 1 diabetes, pramlintide reduced average blood glucose compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMean plasma glucose
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Measurements
Mean plasma glucose
8.3 mmol/L
pramlintide, +/-0.7, profile day
Mean plasma glucose
10.2 mmol/L
placebo, +/-0.8, profile day
Source sentences
Summary
On the profile day, the mean plasma glucose (8.3+/-0.7 v 10.2+/-0.8 mmol/L, P = .04) and postprandial concentrations (incremental areas under the curve [AUCs] from 0 to 120 minutes) were significantly decreased during pramlintide administration (P < .01 for both) despite comparable circulating insul…
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123902
03HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, pramlintide reduced postprandial glucose AUC versus placebo.
In plain wordsIn men with type 1 diabetes, pramlintide reduced glucose after meals compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose AUC
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Source sentences
Summary
On the profile day, the mean plasma glucose (8.3+/-0.7 v 10.2+/-0.8 mmol/L, P = .04) and postprandial concentrations (incremental areas under the curve [AUCs] from 0 to 120 minutes) were significantly decreased during pramlintide administration (P < .01 for both) despite comparable circulating insul…
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123903
04HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, circulating insulin was comparable during pramlintide and placebo.
In plain wordsIn men with type 1 diabetes, insulin levels were similar with pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeCirculating insulin
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Measurements
Circulating insulin
359 pmol/L
pramlintide, +/-41, profile day
Circulating insulin
340 pmol/L
placebo, +/-35, profile day
Source sentences
Summary
On the profile day, the mean plasma glucose (8.3+/-0.7 v 10.2+/-0.8 mmol/L, P = .04) and postprandial concentrations (incremental areas under the curve [AUCs] from 0 to 120 minutes) were significantly decreased during pramlintide administration (P < .01 for both) despite comparable circulating insul…
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123904
05HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, pramlintide reduced blood glycerol versus placebo.
In plain wordsIn men with type 1 diabetes, pramlintide reduced blood glycerol compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBlood glycerol
Study
n = 14
Comparator
Placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Measurements
Blood glycerol
0.029 mmol/L
pramlintide, +/-0.004
Blood glycerol
0.04 mmol/L
placebo, +/-0.004
Source sentences
Summary
Mean blood glycerol values were reduced (0.029+/-0.004 v 0.040+/-0.004 mmol/L, P = .01) and blood alanine levels were elevated (0.274+/-0.012 v 0.246+/-0.008 mmol/L, P = .03) after pramlintide versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123905
06HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, pramlintide increased blood alanine versus placebo.
In plain wordsIn men with type 1 diabetes, pramlintide increased blood alanine compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseBlood alanine
Study
n = 14
Comparator
Placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Measurements
Blood alanine
0.274 mmol/L
pramlintide, +/-0.012
Blood alanine
0.246 mmol/L
placebo, +/-0.008
Source sentences
Summary
Mean blood glycerol values were reduced (0.029+/-0.004 v 0.040+/-0.004 mmol/L, P = .01) and blood alanine levels were elevated (0.274+/-0.012 v 0.246+/-0.008 mmol/L, P = .03) after pramlintide versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123906
07HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, blood lactate did not differ between pramlintide and placebo.
In plain wordsIn men with type 1 diabetes, blood lactate was similar with pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeBlood lactate
Study
n = 14
Comparator
Placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Source sentences
Summary
Blood lactate concentrations did not differ during the two regimens.
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123907
08HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, pramlintide reduced glucagon AUC after breakfast versus placebo.
In plain wordsIn men with type 1 diabetes, pramlintide reduced glucagon after breakfast compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseGlucagon AUC after breakfast
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Source sentences
Summary
During pramlintide administration, the AUC (0 to 120 minutes) for plasma glucagon after breakfast was diminished (P = .02), and a similar trend was observed following lunch.
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123908
09HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, pramlintide showed a trend toward lower glucagon AUC after lunch versus placebo.
In plain wordsIn men with type 1 diabetes, pramlintide showed a trend toward lower glucagon after lunch compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseGlucagon AUC after lunch
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Source sentences
Summary
During pramlintide administration, the AUC (0 to 120 minutes) for plasma glucagon after breakfast was diminished (P = .02), and a similar trend was observed following lunch.
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123909
10HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, pramlintide reduced peak glucagon after breakfast versus placebo.
In plain wordsIn men with type 1 diabetes, pramlintide reduced peak glucagon after breakfast compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePeak glucagon after breakfast
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Measurements
Peak plasma glucagon 60 min after breakfast
45.8 ng/L
pramlintide, +/-7.3
Peak plasma glucagon 60 min after breakfast
72.4 ng/L
placebo, +/-8.0
Source sentences
Summary
In addition, peak plasma glucagon concentrations 60 minutes after breakfast (45.8+/-7.3 v 72.4+/-8.0 ng/L, P = .005) and lunch (47.6+/-9.0 v 60.9+/-8.2 ng/L, P = .02) were both decreased following pramlintide.
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123910
11HumanNon-randomized trialEfficacy outcome
In men with type 1 diabetes, pramlintide reduced peak glucagon after lunch versus placebo.
In plain wordsIn men with type 1 diabetes, pramlintide reduced peak glucagon after lunch compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePeak glucagon after lunch
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
30 microg four times daily · 4 weeksAs given in this study (human).
Measurements
Peak plasma glucagon 60 min after lunch
47.6 ng/L
pramlintide, +/-9.0
Peak plasma glucagon 60 min after lunch
60.9 ng/L
placebo, +/-8.2
Source sentences
Summary
In addition, peak plasma glucagon concentrations 60 minutes after breakfast (45.8+/-7.3 v 72.4+/-8.0 ng/L, P = .005) and lunch (47.6+/-9.0 v 60.9+/-8.2 ng/L, P = .02) were both decreased following pramlintide.
2 context sentences(design, population, supporting numbers)
Summary · context
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study.
Summary · context
Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed.
Report a problemFND-1042123911

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.